C 9101
Alternative Names: C-9101Latest Information Update: 18 Feb 2008
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 14 Dec 2004 Phase-I clinical trials in Rheumatic disorders in USA (unspecified route)